Diverse molecular data demonstrate that commercially available medicinal leeches are not Hirudo medicinalis
Research article published in Proceedings. Biological sciences (2007)
Abstract
The European medicinal leech is one of vanishingly few animal species with direct application in modern medicine. In addition to the therapeutic potential held by many protease inhibitors purified from leech saliva, and notwithstanding the historical association with quackery, Hirudo medicinalis has been approved by the United States Food and Drug Administration as a prescription medical device. Accurate annotation of bioactive compounds relies on precise species determination. Interpretations of developmental and neurophysiological characteristics also presuppose uniformity within a model species used in laboratory settings. Here, we show, with mitochondrial sequences and nuclear microsatellites, that there are at least three species of European medicinal leech, and that leeches marketed as H. medicinalis are actually Hirudo verbana. Beyond the obvious need for reconsideration of decades of biomedical research on this widely used model organism, these findings impact regulatory statutes and raise concerns for the conservation status of European medicinal leeches.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
The European medicinal leech is one of vanishingly few animal species with direct application in modern medicine. In addition to the therapeutic potential held by many protease inhibitors purified from leech saliva, and notwithstanding the historical association with quackery, Hirudo medicinalis has been cleared by the United States FDA via 510(k) premarket notification...
Why This Matters for Hirudotherapy
This study used mitochondrial DNA sequences and nuclear microsatellites to examine the species identity of commercially available European medicinal leeches, demonstrating that leeches marketed as Hirudo medicinalis are actually Hirudo verbana and that at least three distinct European medicinal leech species exist. This finding is directly relevant to hirudotherapy because accurate species determination is foundational to annotating bioactive salivary compounds, ensuring reproducibility of biomedical research on leech models, and maintaining regulatory compliance—particularly given that H. medicinalis is noted as FDA-approved as a medical device while the actual species in commercial circulation may differ. The work is strictly molecular and taxonomic in scope, providing no clinical outcome or therapeutic efficacy data. Its relevance to ASH's domain is nevertheless immediate and substantive, as it addresses a fundamental identification problem at the center of leech-based therapy, pharmacology, and conservation.
Citation
Diverse molecular data demonstrate that commercially available medicinal leeches are not Hirudo medicinalis.
Siddall M et al. · Proceedings. Biological sciences, 2007
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026